_256_384.jpg)
News | March 01, 2024
Suven announces merger of Cohance Lifesciences
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The plant will drive pharmaceutical innovation in the Northeastern India
The facility will accommodate over 1,500 employees
The contract awarded to Kilitch Estro Biotech PLC entails the supply of pharmaceuticals with an order size amounting to US$ 9.13 million
VeerHealth Care will be raising Rs. 8 crores through bank borrowings
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
_256_384.jpg)
The Vice President also highlighted the importance of preventive healthcare and fitness
Subscribe To Our Newsletter & Stay Updated
